Literature DB >> 22297896

Cerebellar ataxia associated to anti-glutamic acid decarboxylase autoantibody (anti-GAD): partial improvement with intravenous immunoglobulin therapy.

José Luiz Pedroso, Pedro Braga-Neto, Livia Almeida Dutra, Orlando G P Barsottini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22297896     DOI： 10.1590/s0004-282x2011000700030

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN： 0004-282X            Impact factor:   1.420


× No keyword cloud information.
  10 in total

1.  Paraneoplastic neurological syndromes: general treatment overview.

Authors:  Aurélien Viaccoz; Jérôme Honnorat
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

2.  Low-Titre GAD Antibody-Associated Late-Onset Cerebellar Ataxia with a Significant Clinical Response to Intravenous Immunoglobulin Treatment.

Authors:  Timotej Petrijan; Marija Menih
Journal:  Cerebellum       Date:  2017-08       Impact factor: 3.847

Review 3.  Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies: review.

Authors:  José Fidel Baizabal-Carvallo; Marlene Alonso-Juarez
Journal:  J Neural Transm (Vienna)       Date:  2017-07-08       Impact factor: 3.575

4.  Intravenous immunoglobulin and rituximab for cerebellar ataxia with glutamic acid decarboxylase autoantibodies.

Authors:  Vincent Planche; Ana Marques; Miguel Ulla; Marc Ruivard; Franck Durif
Journal:  Cerebellum       Date:  2014-06       Impact factor: 3.847

5.  Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.

Authors:  Helena Ariño; Nuria Gresa-Arribas; Yolanda Blanco; Eugenia Martínez-Hernández; Lidia Sabater; Mar Petit-Pedrol; Idoia Rouco; Luis Bataller; Josep O Dalmau; Albert Saiz; Francesc Graus
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

Review 6.  GAD antibodies in neurological disorders - insights and challenges.

Authors:  Francesc Graus; Albert Saiz; Josep Dalmau
Journal:  Nat Rev Neurol       Date:  2020-05-26       Impact factor: 42.937

Review 7.  Anti-glutamic acid decarboxylase antibody positive neurological syndromes.

Authors:  Hassaan Tohid
Journal:  Neurosciences (Riyadh)       Date:  2016-07       Impact factor: 0.906

Review 8.  Neurological Syndromes Associated with Anti-GAD Antibodies.

Authors:  Maëlle Dade; Giulia Berzero; Cristina Izquierdo; Marine Giry; Marion Benazra; Jean-Yves Delattre; Dimitri Psimaras; Agusti Alentorn
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

9.  Anti-glutamic acid decarboxylase antibody (GAD) syndromes may have more aggressive disease course in African Americans and early onset of presentation compare to Caucasians group.

Authors:  Shitiz Sriwastava; Meghana Srinivas; Anila Kanna; Kalyan Yarraguntla; Abbas Jowkar; Edwin George
Journal:  eNeurologicalSci       Date:  2019-09-11

Review 10.  Guidelines for treatment of immune-mediated cerebellar ataxias.

Authors:  Hiroshi Mitoma; Marios Hadjivassiliou; Jérôme Honnorat
Journal:  Cerebellum Ataxias       Date:  2015-11-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.